Propanc Biopharma Inc

Propanc Biopharma appoints Ralf Brandt to scientific advisory board as it develops cancer patent

Propanc Biopharma Inc (OTCMKTS:PPCB) chief executive officer James Nathanielsz speaks to Procative Investors about the company's recent appointment of Dr Ralf Brandt to its scientific advisory board.
The company is developing patents for cancer treatment that focuses on solid tumours, using its lead product PRP, and recently received a notice of allowance for its US patent formula. 
Nathanielsz says: "This is quite an exciting development because in the US, biologicals, especially ones that are naturally derived, are quite often hard to patent.
"We've been able to identify claims that we believe were novel and inventive and the US Patent and Trademark Office agreed - this is probably the highest level of protection needed in the biggest market in the world."

Quick facts: Propanc Biopharma Inc

Price: $0.80

Market: OTCQB
Market Cap: $673.28 k

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Propanc Biopharma Inc named herein, including the promotion by the Company of Propanc Biopharma Inc in any Content on the Site, the Company...



Propanc Biopharma boosts its patent portfolio for its anti-cancer therapy

Propanc Biopharma Inc (OTCMTKS:PPCBD) CEO James Nathanielsz tells Proactive Investors the company has boosted its intellectual property portfolio for its anti-cancer technology currently in development. The biopharmaceutical company’s portfolio now has 65 patents either in force or...

on 06/28/2019

2 min read